New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications
Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...
Scouted: ‘Nature’s Ozempic’? Experts Weigh in on the Budding GLP-1 Supplement Boom
Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...
HealthDay on MSN1d
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...
Endocrinology Advisor3d
Real-World Effectiveness of GLP-1 RA vs DPP4i in Moderate to Severe CKD Explored
In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).
Renal & Urology News2d
GLP-1 Receptor Agonists May Have Broader Range of Benefits, Risks
With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...
pulmonologyadvisor1d
GLP-1 Receptor Agonists Tied to Risks and Benefits Beyond Weight Loss
For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...
EurekAlert!1d
Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among us adults with overweight or obesity
In this cohort study, most patients with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy within 1 year, but those without type 2 diabetes had higher ...
pulmonologyadvisor1d
Websites Selling Compounded GLP-1 RAs Often Misinform Consumers
Websites that sell compounded GLP-1 RAs often partially inform or misinform consumers, including with respect to US FDA approval.
Medscape9d
GLP-1 Benefits, Risks Detailed in ‘Atlas’ Mapping Outcomes
The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...
Glucagon-like peptide-1 receptor agonists tied to higher thyroid cancer risk in first year of treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...
Monthly Prescribing Reference9d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online January ...
FDA approves Ozempic to help reduce risk of worsening chronic kidney disease
The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...